Introduction {#S1}
============

The leucine-rich repeat kinase 2 (LRRK2) is a large multidomain protein that is associated with familiar and sporadic Parkinson's disease (PD) ([@B35]). In its enzymatic core region, LRRK2 harbors both a Ras of complex (Roc) GTPase domain and a kinase domain linked via the C-terminal of Roc (COR) domain. Those catalytically active domains encompass the most severe PD-associated mutations namely G2019S, I2020T in the kinase domain, and R1441C/G/H in the Roc domain ([@B60]; [@B37]). Additionally, Armadillo (ARM), Ankyrin (ANK), and leucine-rich repeat (LRR) domains at the N-terminus as well as a WD40 domain at the C-terminus confer structural integrity and act as scaffolds for protein-protein interactions. This complex domain architecture is assumed to regulate not only enzymatic activities of the GTPase and the kinase but also allows for spatiotemporal control throughout the cell ([@B17]; [@B42]). Members of the Rab GTPase family were recently found to serve both as substrates as well as functional modulators of LRRK2 ([@B50]). As one of those, Rab29 recruits LRRK2 to the *trans*-Golgi network ([@B31]; [@B42]). Besides Rab-induced localization to membranes, LRRK2 also associates with the cytoskeleton. In this context, skein-like structures around microtubules are induced by pathogenic mutations such as R1441C or I2020T or specific kinase inhibitors ([@B26]; [@B5]; [@B46]). Members of the 14-3-3 protein family are known LRRK2 interactors enabling, both spatial control throughout the cell, as well as regulation of kinase activity ([@B28]).

In humans, seven 14-3-3 isoforms (β, γ, ε, ζ, η, θ, σ) have been identified which regulate activity, multimerization as well as the cellular localization of their target proteins (reviewed in [@B1]). By acting as scaffolds, either homodimeric or heterodimeric, 14-3-3 proteins orchestrate numerous signaling pathways. Each 14-3-3 dimer is capable of binding to two target sequences simultaneously, thereby allowing for communication between different sites of the same polypeptide chain or even multiple proteins ([@B14]). Despite their high sequence similarities, the seven human isoforms have different functions and interaction partners which link them to specific disease phenotypes ([@B14]). 14-3-3 proteins have been associated with neurodegenerative diseases such as Alzheimer's disease (ζ) and PD (γ, ϵ, ζ, θ) ([@B49]; [@B21]). In PD, pathogenic LRRK2 mutations such as G2019S alter kinase activity and can be modulated by 14-3-3 interactions ([@B28]). Furthermore, 14-3-3 proteins drive translocation of LRRK2 into exosomes finally leading to a secretion into the urine ([@B16]). Another property of 14-3-3 binding to LRRK2 is protection from proteasomal degradation by inhibiting ubiquitylation and other posttranslational modifications ([@B59]).

The binding pocket of 14-3-3 proteins is positively charged. Therefore, phosphorylation of specific sequences within target proteins can enhance affinity ([@B14]). Yaffe and coworkers first defined sequence motifs enabling 14-3-3 interaction ([@B57]). One of those binding motifs, R-X-X-p\[S/T\]-X-P, resembles consensus sequences of AGC-kinases and is phosphorylated by the protein kinase A (PKA) with the PKA consensus sequence R-R-X-\[S/T\] ([@B25]; [@B47]). Our group described the PKA phosphosite S1444 (P0 position) within the Roc-domain and could demonstrate that this position enables binding of 14-3-3 proteins. 14-3-3 interaction is impaired in R1441C/G/H, one of the most common PD-related mutations, which represents the P-3 position of the PKA consensus sequence ([@B38]). This could be confirmed by [@B52] for 14-3-3γ. The N-terminal phosphorylation cluster, located between the ANK and LRR domain of LRRK2, encompasses the residues S910 and S935 which were identified as major 14-3-3 binding sites ([@B15]; [@B39]). Another motif, defined as p\[S/T\]-X~1--2~-COOH enables binding of 14-3-3 proteins to the C-terminus of the respective interaction partner ([@B10]).

Here, we investigated the interaction of LRRK2 and all seven human 14-3-3 isoforms which we could confirm with pull-down experiments. Using LRRK2-derived peptides, we quantified binding to recombinant 14-3-3 proteins to discriminate isoform specificity toward the already described sites in the N-terminal phosphorylation cluster (S910 and S935) and the Roc domain (S1444). Finally, we could link the potential pathogenic mutation Q930R ([@B4]) to altered 14-3-3 binding and identified the autophosphorylation site T2524 ([@B41]) at the C-terminus of LRRK2 as a so far not described 14-3-3 binding site.

Results {#S2}
=======

The interaction of 14-3-3 proteins with certain binding sites on LRRK2 has been described by several groups. Yet a comprehensive study comparing all seven human isoforms targeting these sites in LRRK2 is lacking. In an initial experiment we investigated binding of all human 14-3-3 isoforms to LRRK2 full-length protein by performing pull-down assays. For this, we co-expressed the respective 14-3-3 isoforms and FLAG-Strep-Strep-tagged LRRK2 in HEK293T cells. We were able to co-precipitate all 14-3-3 isoforms with LRRK2, although binding of σ was barely detectable ([Figure 1](#F1){ref-type="fig"}). However, binding of 14-3-3 proteins to full-length LRRK2, as shown here, does not allow for a discrimination between distinct sites. Furthermore, the phosphostatus of the respective 14-3-3 interaction sites cannot be controlled in full-length LRRK2.

![Pull-down experiments demonstrate binding of 14-3-3 isoforms to full-length LRRK2. HEK293T cells were transfected with pcDNA3.0 plasmids encoding FLAG-Strep-Strep-LRRK2 or FLAG-HA-14-3-3 as indicated with (+) and the respective isoform. (−) indicates cells that were not transfected with LRRK2 or both, 14-3-3 and LRRK2 (last lane). **(A)** 14-3-3 isoforms were co-precipitated by capturing LRRK2 with Strep-Tactin resin. Expression of proteins is shown with the input control of cell lysates **(B)**. LRRK2 and 14-3-3 proteins were detected using α-FLAG antibodies and visualized using fluorescently labeled secondary α-mouse IgG antibodies.](fnins-14-00302-g001){#F1}

![Cartoon: Domain structure of LRRK2 indicating the distinct 14-3-3 interaction sites (arrows). Binding of 14-3-3 to LRRK2-derived peptides ([Table 1](#T1){ref-type="table"}) was quantified with fluorescence polarization (FP). Dilution series of 14-3-3γ were measured with the indicated fluorescently labeled peptides. While non-phosphorylated peptides (gray) did not show binding, the doubly phosphorylated pS910/pS935 **(A)** demonstrated the highest affinity. From the singly phosphorylated wild type peptides, pS1444 **(B)** showed the highest affinity. The possible pathogenic mutation Q930R enables high affinity binding to pS935 **(C)**. Data points shown as circles were excluded from non-linear fits. Phosphorylated T2524 **(D)** clearly binds with micromolar affinity. All data points are means of duplicate measurements with error bars representing the standard error of mean (SEM).](fnins-14-00302-g002){#F2}

We thus identified and quantified 14-3-3:LRRK2 interactions in a comprehensive study based on peptide sequences, focusing on isolated binding sites and isoform specificity. We performed fluorescence polarization (FP) assays using recombinantly expressed proteins of the seven human 14-3-3 isoforms. For this purpose, we designed fluorescently labeled LRRK2 peptides ([Table 1](#T1){ref-type="table"}) covering the 14-3-3 binding sites S910, S935, and S1444. Mass spectrometry studies previously revealed T2524 as a LRRK2-autophosphorylation site ([@B41]). This position is located at the C-terminus of LRRK2 and thus shows similarity to the 14-3-3 binding mode III \[p(S/T)-X~1--2~-COOH\]. We therefore designed phospho- and non-phosphopeptides comprising T2524 at the very C-terminus of LRRK2.

###### 

Peptides covering potential 14-3-3 binding sites: S910, S933, S935, S1443, S1444 and T2524.

  Peptide Name        Sequence
  ------------------- -----------------------------------------------
  S910                SFLVKKKSN**S**ISVGEFYRD
  pS910               SFLVKKKSN**pS**ISVGEFYRD
  S935                SPNLQRHSN**S**LGPIF
  pS935               SPNLQRHSN**pS**LGPIF
  S933                RCSPNLQRH**S**NSLGPIFDH
  pS933               RCSPNLQRH**pS**NSLGPIFDH
  Q930R               RCSPNL**[R]{.ul}**RH**S**N**S**LGPIFDH
  Q930R/pS933         RCSPNL**[R]{.ul}**RH**pS**N**S**LGPIFDH
  Q930R/pS935         RCSPNL**[R]{.ul}**RH**S**N**pS**LGPIFDH
  Q930R/pS933/pS935   RCSPNL**[R]{.ul}**RH**pS**N**pS**LGPIFDH
  S910/S935           KKSN **S**ISVGEFYRDAVLQRCSPNLQRHSN**S**LGPIF
  pS910/S935          KKSN**pS**ISVGEFYRDAVLQRCSPNLQRHSN**S**LGPIF
  S910/pS935          KKSN**S**ISVGEFYRDAVLQRCSPNLQRHSN**pS**LGPIF
  pS910/pS935         KKSN**pS**ISVGEFYRDAVLQRCSPNLQRHSN**pS**LGPIF
  S1443/S1444         LFNIKARA**SS**SPVILVGT
  pS1443              LFNIKARA**pSS**SPVILVGT
  pS1444              LFNIKARA**SpS**SPVILVGT
  pS1443/pS1444       LFNIKARA**pSpS**SPVILVGT
  R1441C              LFNIKA**[C]{.ul}**A**SS**SPVILVGT
  R1441C/pS1444       LFNIKA**[C]{.ul}**A**SpS**SPVILVGT
  T2524               HIEVRKELAEKMRR**T**SVE
  pT2524              HIEVRKELAEKMRR**pT**SVE

All peptides were synthesized with N-terminal fluorescein labels for FP measurements.

15-19-mer peptide variants comprising S910, S935, S1444, or T2524 ([Table 1](#T1){ref-type="table"}) were first screened for binding toward 14-3-3γ ([Figure 2](#F2){ref-type="fig"} and [Supplementary Figure S1](#TS1){ref-type="supplementary-material"}). While no notable binding was detected for all non-phosphorylated peptides, the phosphorylated peptide pS910 demonstrated micromolar binding affinity ([Supplementary Figure S1A](#TS1){ref-type="supplementary-material"}). However, no binding was detected for the phosphorylated peptide variant pS935 ([Supplementary Figure S1A](#TS1){ref-type="supplementary-material"}). [@B4] described the possible pathogenic mutation Q930R in LRRK2. This mutation may render S933 into a potential PKA phosphorylation site as the server-based tool NetPhos3.1 predicted with a score of 0.86 ([@B6]). A phosphorylation close to this mutated residue would subsequently generate a 14-3-3 interaction site as predicted with a consensus score of 0.71 using 14-3-3-Pred ([@B33]). Our peptide studies revealed that neither the Q930R mutation nor the additional phosphorylation in pS933 could induce binding of 14-3-3γ ([Figure 2C](#F2){ref-type="fig"}). In this context, we assumed that the mutation Q930R may influence binding of 14-3-3γ to pS935 (14-3-3-Pred score: 0.95). Strikingly, the Q930R mutation enabled a nanomolar affinity to pS935, which previously showed no binding in the singly phosphorylated peptides ([Figure 2C](#F2){ref-type="fig"}, [Table 2](#T2){ref-type="table"}, and [Supplementary Figure S1A](#TS1){ref-type="supplementary-material"}).

###### 

Binding affinities of human 14-3-3 isoforms toward LRRK2-derived phosphopeptides as measured by FP.

  14-3-3 Isoform   β            γ             ϵ            ζ            η            θ             σ
  ---------------- ------------ ------------- ------------ ------------ ------------ ------------- ------------
  pS910/pS935      21.1 ± 4.2   3.2 ± 0.5     12.4 ± 0.9   4.8 ± 2.2    4.8 ± 1.8    9.5 ± 2.0     60.6 ± 6.9
  Q930R/pS935      29.5 ± 9.6   11.1 ± 10.7   48.5 ± 5.6   23.9 ± 0.1   13.3 ± 0.5   73.1 ± 19.7   350 ± 74
  pS1444           183 ± 25     106 ± 4       \>1 μM       476 ± 165    85 ± 10      195 ± 42      802 ± 261
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-values (nM) are given as means of at least three independent measurements with standard deviation (SD).

With a *K*~*D*~-value of 106 nM, pS1444 featured the highest affinity of all singly phosphorylated wild type peptides ([Figure 2B](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). To investigate whether S1443, a reported PKA phosphorylation site ([@B38]), affects 14-3-3 binding, we generated another set of phosphopeptides comprising this position. While pS1443 alone did not allow for binding, the doubly phosphorylated peptide pS1443/pS1444 reduced binding to 14-3-3γ compared to pS1444 ([Figure 2B](#F2){ref-type="fig"}). To further examine the influence of the familial PD mutation R1441C on 14-3-3 binding to the site S1444 we tested a peptide encompassing both R1441C and pS1444. Including this PD-associated mutation into the peptide (R1441C/pS1444) strongly decreased the nanomolar affinity of pS1444 alone ([Supplementary Figure S1B](#TS1){ref-type="supplementary-material"}). Again, the non-phosphorylated peptide variant encompassing the mutation R1441C displayed no binding. Finally, we tested binding to the autophosphorylation site T2524 ([@B41]). Phospho and non-phosphopeptides comprising T2524 at the very C-terminus of LRRK2 were designed and demonstrated micromolar affinities for binding of 14-3-3γ to pT2524 ([Figure 2D](#F2){ref-type="fig"}).

We next analyzed binding of 35-mers which encompass both, S910 and S935 ([Figure 2A](#F2){ref-type="fig"}). Longer peptides were previously shown to exhibit one of the strongest affinities by enabling a dual-binding-mode of 14-3-3 dimers ([@B52]). In line with the short peptide variant pS935 ([Supplementary Figure S1A](#TS1){ref-type="supplementary-material"}), both singly phosphorylated peptides pS910/S935 and S910/pS935 showed only weak interactions. The affinity was drastically increased to 3.2 nM for the doubly phosphorylated peptide pS910/pS935 ([Table 2](#T2){ref-type="table"}). 14-3-3γ, again, did not bind non-phosphorylated S910/S935 ([Figure 2A](#F2){ref-type="fig"}).

In the following analysis, binding of all seven human 14-3-3 isoforms to the above-mentioned binding sites in LRRK2 was quantified. Binding of pS910 was demonstrated for all isoforms but ϵ and σ ([Supplementary Figure S2A](#TS1){ref-type="supplementary-material"}). The highest affinities, yet in a micromolar range, were identified for γ and η followed by β and ζ while θ demonstrated the weakest binding. Under the same conditions no binding could be detected for pS935 with any 14-3-3 isoform ([Supplementary Figure S2B](#TS1){ref-type="supplementary-material"}). As expected, no non-phosphorylated control peptide bound to any isoform ([Supplementary Figure S2](#TS1){ref-type="supplementary-material"}). For the longer singly phosphorylated peptides, pS910/S935 and S910/pS935 no isoform specificity could be distinguished ([Supplementary Figure S3](#TS1){ref-type="supplementary-material"}). The doubly phosphorylated pS910/pS935 peptide enhanced binding toward all 14-3-3 isoforms to nanomolar affinities ([Figure 3A](#F3){ref-type="fig"}). This result indicates that both phosphosites are crucial for high affinity binding. The obtained *K*~*D*~-values of the isoforms ranged from 4.8 nM for γ to 61 nM for σ ([Table 2](#T2){ref-type="table"}). Interestingly, the singly phosphorylated peptide Q930R/pS935 displays affinities from as high as 11 nM to as low as 350 nM ([Figure 3C](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). In [Figure 4](#F4){ref-type="fig"}, the binding patterns of all 14-3-3 isoforms are visualized in a graphical overview.

![Isoform-specific binding of the LRRK2-derived peptides pS910/pS935 **(A)**, pS1444 **(B)**, Q930R/pS935 **(C)** and pT2524 **(D)** to all seven human 14-3-3 isoforms. *K*~*D*~-values were obtained with at least three independent measurements and are listed in [Table 2](#T2){ref-type="table"}. The resulting binding patterns are visualized in [Figure 4](#F4){ref-type="fig"}. Data points are means of duplicate measurements with error bars representing the standard error of mean (SEM).](fnins-14-00302-g003){#F3}

![Pattern of 14-3-3 binding to distinct sites in LRRK2 based on FP experiments. Colors represent 14-3-3 isoforms as used for the binding curves ([Figure 3](#F3){ref-type="fig"} and [Supplementary Figure S2](#TS1){ref-type="supplementary-material"}). For the singly phosphorylated peptides Q930R/pS935 and pS1444 as well as for the doubly phosphorylated peptide pS910/pS935 *K*~*D*~-values were in the nanomolar range. Micromolar affinities were found for pS910 and pT2524 not allowing for absolute determination of *K*~*D*~-values. No binding is indicated with asterisks.](fnins-14-00302-g004){#F4}

pS1444 shows the highest affinities of all singly phosphorylated wild type peptides to all 14-3-3 isoforms ([Figure 3B](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). The isoforms γ and η exhibited the strongest binding with *K*~*D*~-values of approximately 100 nM, followed by β and θ with approximately 200 nM. While σ bound with an affinity of about 800 nM, the *K*~*D*~ of ϵ was above 1 μM. The isoform-specific binding pattern of pS1444 well compares to the one of pS910 ([Figure 4](#F4){ref-type="fig"}). Consequently, binding of all 14-3-3 isoforms toward pS1444 was detrimentally affected by an additional phosphorylation of S1443 as shown for γ, while binding to pS1443 was not demonstrated for any isoform ([Supplementary Figure S5A](#TS1){ref-type="supplementary-material"}). All 14-3-3 isoforms interacted with R1441C/pS1444 displaying affinities in the micromolar range ([Supplementary Figure S5B](#TS1){ref-type="supplementary-material"}). However, we were not able to quantify this low affinity binding and thus could not distinguish an isoform-dependency.

We finally tested isoform-specific binding of human 14-3-3 proteins to the C-terminal autophosphorylation site using the peptide pT2524 ([Figure 3D](#F3){ref-type="fig"} and [Supplementary Figure S6](#TS1){ref-type="supplementary-material"}). Binding affinities were in the low micromolar range, with σ showing the worst binding. The observed binding pattern again well resembled those of the singly phosphorylated peptides pS910 and pS1444 ([Figure 4](#F4){ref-type="fig"}).

Discussion {#S3}
==========

Malfunction of LRRK2 is correlated to PD pathogenesis suggesting that LRRK2 activity needs to be tightly controlled ([@B35]). Upstream and downstream regulators of LRRK2 have been described including kinases (e.g., PKA, casein kinase 1α), phosphatases (e.g., protein phosphatase 1), and small G-proteins (e.g., Rab29) ([@B32]; [@B8]; [@B19]; [@B42]). Proteins of the highly conserved 14-3-3 family represent another class of interaction partners providing control on a cellular level. 14-3-3 isoforms form homodimers as well as heterodimers by this broadening the spectrum of modulation ([@B24]). Binding of 14-3-3 proteins has been demonstrated to influence kinase activity, the phosphorylation state, and the ubiquitylation state of LRRK2 ([@B39]; [@B59]; [@B28]).

In this study we investigated the interaction of all human 14-3-3 isoforms with three different binding regions in LRRK2. We used two different approaches to investigate direct interaction between LRRK2 and the human 14-3-3 isoforms. Based on pull-down assays we qualitatively showed that all 14-3-3 isoforms except for 14-3-3σ interact with LRRK2 ([Figure 1](#F1){ref-type="fig"}), confirming results by [@B39] and [@B30]. LRRK2, however, is a large multidomain protein that occurs in different conformational states potentially leading to a structure-dependent protection of putative 14-3-3 binding sites. Since the accessibility of those sites on full-length protein could be limited in pull-down assays, we intended to focus our studies by reducing complexity of the interaction utilizing isolated peptide sequences. FP was therefore employed to quantitatively analyze binding affinities of 14-3-3 proteins to LRRK2-derived peptides. Our results demonstrate binding of 14-3-3 proteins in an isoform-specific manner to distinct regions in LRRK2. Within the N-terminal phosphorylation cluster we attributed the possible pathogenic mutant Q930R ([@B4]) to alter the affinity of 14-3-3 proteins toward S935. Finally, we identified phosphorylated T2524 as a so far not described interaction site at the very C-terminus of LRRK2.

14-3-3 Interaction With the N-Terminal Phosphorylation Cluster {#S3.SS1}
--------------------------------------------------------------

The N-terminus of LRRK2 encompasses a constitutive phosphorylation cluster between the ANK and the LRR domain. In this region, the sites S860, S910, S935, S955, and S973 have been described most likely to be phosphorylated by upstream kinases ([@B18]; [@B39]; [@B13]). [@B39] established S910 and S935 as major 14-3-3 binding sites which were shown later to be phosphorylated by PKA ([@B30]; [@B38]).

A peptide encompassing pS910, six amino acids longer than the one employed by [@B52], exhibited the strongest 14-3-3 interaction site within the N-terminal phosphorylation cluster ([Supplementary Figure S2A](#TS1){ref-type="supplementary-material"}). Our studies revealed micromolar affinities for the 14-3-3 isoforms except σ and ϵ and could thereby confirm previous 14-3-3γ data of [@B52]. Although they observed a similar binding for the peptides pS910 and pS935, we could not detect binding of our peptide pS935 to any 14-3-3 isoform ([Supplementary Figure S2B](#TS1){ref-type="supplementary-material"}).

Based on primary sequence predictions, S933 is a potential phosphorylation site which is in close proximity to the possible pathogenic mutation Q930R ([@B4]; [@B18]). This mutation may render S933 into a potential PKA phosphorylation site and subsequently generates a potential 14-3-3 interaction site. However, no 14-3-3 binding was detectable for either pS933 or Q930R/pS933 ([Supplementary Figure S4](#TS1){ref-type="supplementary-material"}). Interestingly, when including the Q930R mutation into a peptide encompassing pS935, 14-3-3 affinities for all isoforms were drastically increased to nanomolar *K*~*D*~-values ([Figures 2C](#F2){ref-type="fig"}, [3C](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). This mutation may generate a possible recognition site of protein kinase B (PKB/AKT) with the consensus sequence **R**-X-R-X-X-\[S/T\]-**y** (*y* = hydrophobic residue) ([@B3]; [@B40]). The impact of Q930R on 14-3-3:LRRK2 interaction may explain PD-association of this mutation.

14-3-3 proteins can also be subject to post-translational modifications such as phosphorylation or acetylation which affects the recognition of target proteins ([@B2]). In this line, phosphorylation of 14-3-3γ by PAK6 weakens its interaction with LRRK2, which in turn causes dephosphorylation of pS935 ([@B9]). These findings indicate that 14-3-3:LRRK2 interaction can be targeted by protein-protein interaction modulators in order to manipulate irregular interactions ([@B53]).

14-3-3 Interaction With the Roc Domain {#S3.SS2}
--------------------------------------

Of all singly phosphorylated wild type peptides, pS1444 exhibits the highest affinity toward all 14-3-3 isoforms ([Figure 3B](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}), which is in line with [@B52]. S1443, adjacent to this position, is phosphorylated by PKA as well, yet incapable of 14-3-3 binding ([Figure 2B](#F2){ref-type="fig"} and [Supplementary Figure S5A](#TS1){ref-type="supplementary-material"}; [@B38]). Compared to pS1444, the doubly phosphorylated peptide pS1443/pS1444 reduced nanomolar binding affinity to micromolar values for all isoforms ([Figure 2B](#F2){ref-type="fig"} and [Supplementary Figure S5A](#TS1){ref-type="supplementary-material"}). We speculate that additional phosphorylation of S1443 could fine tune 14-3-3 interactions. To understand the mutual effect of S1443 and S1444 in a more physiological context, further investigations are required.

The mutational hotspot R1441 with the pathogenic mutations R1441C/G/H/S is located in close proximity to S1444 within the Roc domain ([@B22]; [@B36]; [@B43]). Those mutations are known to decrease GTPase activity ([@B56]) while data on effects of R1441C on kinase activity is inconsistent as discussed by [@B44]. R1441 represents the P-3 position of a PKA consensus sequence **R-**R-X-\[S/T\]-y (*X* = small residue, *y* = large hydrophobic residue) with S1444 as P0 position. Binding of 14-3-3 proteins to the Roc domain depends on phosphorylation of S1444. PKA phosphorylation of this site cannot occur when R1441 is mutated ([@B38]). Comparing the peptides R1441C/pS1444 and pS1444 clearly demonstrates that even if S1444 is phosphorylated, the mutation R1441C itself decreases the affinity to all 14-3-3 isoforms at least by a factor of 30 ([Supplementary Figures S1B, S5B](#TS1){ref-type="supplementary-material"}). On a cellular level, mutations of R1441 result in distinct phenotypes. In R1441C knock-in mice both, phosphorylation of S910 and S935 as well as 14-3-3 binding, are reduced, emphasizing the relevance of this mutational hotspot ([@B39]). R1441G induces a neurite shortening phenotype which can be reduced by overexpression of 14-3-3θ ([@B28]). Another effect of R1441 mutations is the accumulation of LRRK2 in cytoplasmic pools as well as filament formation around microtubules ([@B20]; [@B26]). Interestingly, inhibiting kinase activity of LRRK2 with MLi-2 or LRRK2-IN1 induces a similar phenotype indicating a common mechanism ([@B15]; [@B46]). 14-3-3 proteins may be involved in this mechanism, since overexpression of 14-3-3β, 14-3-3γ or 14-3-3ε rescues phenotypes which are caused by R1441C mutation or by kinase inhibition ([@B16]; [@B5]). Alanine substitution of the 14-3-3 binding site S1444 resulted in an increased dot-like localization but not in altered LRRK2-IN1 induced filament formation ([@B5]).

14-3-3 Interaction With the C-Terminal Helix {#S3.SS3}
--------------------------------------------

As we demonstrated micromolar affinities of all 14-3-3 isoforms to phosphorylated T2524, we assume a specific role of the C-terminus in regulating LRRK2 function ([Figure 3D](#F3){ref-type="fig"}). Binding of 14-3-3 proteins occurs to three motifs in target proteins: With p\[S/T\]-X~1--2~-COOH a mode III binding motif, typically accompanied by upstream arginines, is generated at C-termini of target proteins ([@B10]). Although the sequence surrounding T2524 (R-R-pT-S-V-E-COOH) does not perfectly match this motif, we confirmed this autophosphorylation site as a C-terminal 14-3-3 binding site. In interleukin nine receptor alpha chain (IL-9Rα) for example, a phosphorylated serine is also located four amino acids upstream of the C-terminus, still allowing for interaction with 14-3-3 proteins ([@B48]).

The C-terminus appears to be essential for proper LRRK2 function as [@B26] could show that deletion of the C-terminal WD40 domain in LRRK2-I2020T results in cytosolic relocalization from a filamentous phenotype. Deletion of the last 29 residues abolished LRRK2 kinase activity, disabled microtubule association as well as interaction with 14-3-3 proteins ([@B45]). Rudenko and colleagues thus speculated, that the C-terminal region might tether the kinase domain in a defined conformation. [@B23] could further narrow down the relevant sequence. Kinase activity was significantly reduced by deletion of the last four amino acids while removing the last seven amino acids completely abolished activity. The structure of a Roc-COR-Kinase-WD40 (RCKW) construct was just determined using cryo-EM, revealing a helical structure interacting with the kinase domain ([@B11]). These results underline the importance of 14-3-3 binding to the C-terminus, which depends on LRRK2 autophosphorylation at T2524. Reduced autophosphorylation could result in a disturbed 14-3-3 binding to T2524. Finally, we speculate that the C-terminal helix might be autophosphorylated as a tethered substrate, allowing 14-3-3 to regulate LRRK2 function.

Avidity Is an Important Factor for 14-3-3:LRRK2 Interaction {#S3.SS4}
-----------------------------------------------------------

The combination of the low affinity peptide pS910 with the non-binding peptide pS935 resulted in the strongest 14-3-3 interaction of all tested peptides displaying affinities from 3 to 61 nM ([Figure 3A](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Those avidity effects were also demonstrated by [@B52] for 14-3-3γ with other peptides comprising two LRRK2 phosphorylation sites. Furthermore, the group showed a contribution of the sequence between S910 and S935 on the binding event, while linkers of other doubly phosphorylated peptides had no influence ([@B51]). Additional evidence comes from our study, were Q930R, located in the linker, strongly increases 14-3-3 affinity to S935 ([Figure 3C](#F3){ref-type="fig"}).

Isoform-Specific Influence on 14-3-3:LRRK2 Interactions {#S3.SS5}
-------------------------------------------------------

In this comprehensive study we intended to investigate isoform-specific interactions of 14-3-3 proteins with the respective binding sites. Surprisingly, the resulting 14-3-3 binding patterns were very similar for the peptides pS910, Q930R/pS935, pS910/pS935, pS1444, and pT2524 ([Figure 4](#F4){ref-type="fig"}). All 14-3-3 binding sites of LRRK2 were preferentially bound by the isoforms γ and η, in line with results by [@B30] indicating that γ and η are main interactors of full-length LRRK2. The isoforms β, θ, and ζ demonstrated intermediate binding pattern. Weakest binders are the isoforms ε and in particular σ. As shown here and by [@B39], 14-3-3σ, as a special member of this rather homogenous protein family, does not interact with LRRK2. This isoform is primarily found in epithelial cells ([@B29]) and this points to a minor role of 14-3-3σ in LRRK2 regulation.

This isoform specific binding pattern is based on peptide studies, which in contrast to the pull-down assays does not reflect LRRK2 full-length protein but isolated 14-3-3 binding sites. Considering that LRRK2 is a large multidomain protein which occurs in specific conformational states, the different 14-3-3 binding sites might be dynamically accessible. Binding affinity of 14-3-3 proteins could furthermore be determined by structural properties that cannot be displayed with peptides based on the primary sequence of LRRK2 only. In this line, the LRRK2 protein structure could further affect isoform-specific binding of 14-3-3 proteins which should be addressed in future *in vivo* studies.

Conclusion {#S4}
==========

Tight regulation of LRRK2 activities is required in order to maintain proper function since malfunction has been correlated with pathogenesis of PD ([@B12]). As one major regulator, 14-3-3 proteins appear to have a specific role in LRRK2 associated signaling. The phosphorylation state of LRRK2 is important for conformational control, enzymatic activities but also for protein-protein interactions allowing for spatiotemporal control. Here we demonstrate the opposing effects of the PD associated mutations Q930R and R1441C on 14-3-3 binding: in one case strengthening, in the other case weakening the respective interactions. Furthermore, we identified T2524 as a so far not described 14-3-3 binding site, highlighting the outstanding role of the LRRK2 C-terminus. In combination with the previously described sites S910, S935, and S1444, the autophosphorylation site T2524 may influence LRRK2 function. This could include cellular localization, monomer-dimer dynamics, conformational control, protein-protein interactions as well as enzymatic activities. Based on cryo-TM and cryo-EM studies of LRRK2 full-length and deletion constructs the impact of 14-3-3 proteins can finally be investigated on a structural level ([@B55]; [@B11]). This will allow for a deeper understanding of how posttranslational modifications and 14-3-3 interactions affect LRRK2 biology.

Materials and Methods {#S5}
=====================

Purification of Human 14-3-3 Isoforms {#S5.SS1}
-------------------------------------

Human MBP-tagged 14-3-3 isoforms were expressed from pMAL2CX plasmids \[[@B27], [@B58]\] in *E. coli* BL21DE3 cells. After induction with 0.4 M isopropyl-β-D-thiogalactoside, the protein was expressed for 4 h at room temperature. Cells were lysed in MBP-lysis buffer \[50 mM Tris--HCl pH 7.5, 150 mM NaCl, 5 mM MgCl~2~, 1 mM PMSF, 1× cOmplete Protease Inhibitor EDTA-free (Roche)\] using a French Pressure cell (FRENCH Press, Thermo, United States). Following centrifugation at 42,000 × *g* and 4°C for 30 min, the supernatant was transferred to a Maltose-agarose column (1.5 ml bed volume; New England Biolabs GmbH, Germany). Captured proteins were washed six times with 10 ml wash buffer (50 mM Tris--HCl pH 7.5, 150 mM NaCl, 5 mM MgCl~2~) prior to elution using wash buffer including 15 mM D-maltose. To remove the MBP tag, fusion proteins were incubated with Factor Xa (New England Biolabs GmbH, Germany), at a final concentration of 0.4 μg per 1 mg fusion protein for 24 h at RT following another 72 h at 4°C. Anion exchange chromatography was finally applied to separate residual MBP using a buffer gradient from 20 mM Tris pH 8 to 20 mM Tris pH 8 with 1 M NaCl. For this a RESOURCE Q column (GE Healthcare, United Kingdom) was utilized, employing an ÄKTApurifier (GE Healthcare, United Kingdom) or an NGC Quest Chromatography System (Bio-Rad Laboratories GmbH, Germany).

Cell Culture, Transfection, and Purification of FLAG-Strep-Strep-Tagged LRRK2 {#S5.SS2}
-----------------------------------------------------------------------------

N-terminally FLAG-Strep-Strep-tagged (FSS-) LRRK2 constructs were expressed in HEK293T cells. Plasmids (pcDNA3.0) contained the gene for full-length LRRK2 wild type (NM_198578, 1-2527). Cultivation, transfection and harvesting of cells as well as affinity purification and storage were performed as recently described ([@B46]).

Strep-Tag Pull-Down {#S5.SS3}
-------------------

To investigate binding of all human 14-3-3 isoforms, pull-down assays were performed using the FSS-tagged full-length protein of LRRK2. For this purpose, FSS-LRRK2 was co-expressed with the respective HA-FLAG-tagged human 14-3-3 isoforms (subcloned into pcDNA3.0) in HEK293T cells. Cells of one 15 cm Ø dish were lysed in 1 ml lysis buffer \[20 mM Tris pH 7.5, 150 mM NaCl, 10 mM MgCl~2~, 0.5 mM GDP, 0.5% Tween 20, 1× cOmplete Protease Inhibitor EDTA-free (Roche), PhosSTOP (Roche)\]. Following a 30 min incubation at 4°C, lysates were centrifuged at 15,000 × *g* and 4°C for 20 min and subsequently the whole cell protein concentrations was determined using a Bradford assay ([@B7]). Protein concentrations were adjusted to the lowest concentration to transfer equal amounts to 50 μl bed volume of equilibrated Strep-Tactin Superflow (IBA Goettingen) columns. Excessive and non-specifically bound proteins were removed by washing twice with 0.5 ml Strep-Tactin wash buffer containing 0.5 mM GDP and another five times with wash buffer containing 850 mM NaCl and 1% Tween 20. Finally, proteins were eluted and denatured in 50 μl NuPAGE LDS sample buffer (Thermo Fisher Scientific). Following Western blotting, membranes were incubated with 1:1,500 of the primary antibody ANTI-FLAG M2 (mouse, F3165, Sigma-Aldrich) over night at 4°C. To visualize target proteins, IRDye 800CW goat anti-mouse IgG secondary antibodies (LI-COR, United States) were applied at dilutions of 1:15,000 for 1 h prior to detection with an Odyssey Fc Imaging system (LI-COR, United States). Acquired images were validated using the software Image Studio Lite Version 5.2.5 (LI-COR, United States).

Primary Amino Acid Sequence Predictions {#S5.SS4}
---------------------------------------

The primary amino acid sequence of LRRK2 was obtained from [@B54] and was analyzed with the webserver-based tools NetPhos3.1 and 14-3-3-Pred to predict phosphorylation sites and 14-3-3 binding sites ([@B6]; [@B33]). Mutations were included by substituting the respective residue in the LRRK2 wild type sequence.

Fluorescence Polarization (FP) Direct Binding Assays {#S5.SS5}
----------------------------------------------------

FP was used to determine binding affinities of different phosphorylated and non-phosphorylated peptides derived from LRRK2 sequences (Peps4LS GmbH, Germany) toward human 14-3-3 isoforms. Direct binding assays were performed and evaluated as previously described ([@B38]; [@B34]). Briefly, both dilution series of 14-3-3 isoforms ranging from final concentrations of at least 5 μM down to picomolar concentrations and dilutions of the respective fluorescein-labeled peptide (final conc. 1 nM) were prepared in FP buffer (20 mM MOPS pH 7, 150 mM NaCl, 0.005% CHAPS). Subsequently, samples were mixed in 384-well microtiter plates as duplicates (BRAND plates, pureGrade, black, BRAND GmbH & Co. KG, Germany) in a 1:1 ratio and measured using a CLARIOstar plate reader (BMG LABTECH, Germany). Two protein preparations were utilized for at least two independent replications for all measurements while high affinity binding peptides were particularly measured with a minimum of three independent replications for statistical evaluation. Data was analyzed with GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, United States) by plotting obtained FP signals (mPol) against the logarithmic 14-3-3 protein concentrations. Data points represent means ± standard error of mean (SEM) of duplicates. "Ctrl." indicates the FP signal of fluorescein-labeled peptides without 14-3-3 protein. Sigmoidal dose-response fitting was performed to define *K*~*D*~-values.

Data Availability Statement {#S6}
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ANK

:   ankyrin repeats

ARM

:   armadillo repeats

Cor

:   C-terminal of Roc

FP

:   fluorescence polarization

FSS

:   FLAG-Strep-Strep tag

LRR

:   Leucine-rich repeat

LRRK2

:   Leucine-rich repeat kinase 2

LRRK2-IN1

:   LRRK2 inhibitor 1

MBP

:   maltose-binding protein

MLi2

:   Merck LRRK2 inhibitor 2

PD

:   Parkinson's Disease

PKA

:   Protein kinase A

PKB

:   Protein kinase B

Roc

:   Ras of complex.
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